Literature DB >> 19091781

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

Frédérique Penault-Llorca1, Catherine Abrial, Inès Raoelfils, Philippe Chollet, Anne Cayre, Marie-Ange Mouret-Reynier, Emilie Thivat, Florence Mishellany, Pierre Gimbergues, Xavier Durando.   

Abstract

The current study expands upon previous work using a database of 710 patients treated with neoadjuvant chemotherapy. First, we studied phenotypic characteristics of tumors before and after chemotherapy using the following factors: the mitotic index of the Scarff-Bloom-Richardson grade, Ki-67, cyclin D1, and cyclo-oxygenase-2. Second, the predictive value of these factors on response was assessed. Third, we measured the prognostic impact of these markers post-therapy in comparison with clinical and pathological responses according to the Chevallier and Sataloff classifications. Patients were treated using different neoadjuvant chemotherapy combinations, mainly in successive prospective phase II trials. They received a median number of six cycles (range, 1-9). After neoadjuvant chemotherapy, patients underwent surgery and radiotherapy. In cases of important residual disease, some received additional courses of chemotherapy. In addition, menopausal patients with hormone receptor-positive tumors received tamoxifen for 5 years. According to our analysis, we found significant variations before and after neoadjuvant chemotherapy only for cyclin D1 and the mitotic index. Concerning the predictive value of biomarkers for response, Ki-67 and the mitotic index were predictive on univariate analysis, both for objective clinical and pathological complete responses. Because these two factors were correlated, no multivariate analyses were conducted. We then assessed the prognostic impact of the biopathological factors. When the factors were measured before chemotherapy, all were prognostic. When evaluated after chemotherapy, the mitotic index, objective clinical response, and pathological complete response were prognostic. Because these factors were correlated, no multivariate model was done. The main clinical fact is that there were significant correlations between clinical and pathological responses and variations in the biological factors studied.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091781     DOI: 10.1634/theoncologist.2008-0073

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  24 in total

1.  ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Xi-ru Li; Mei Liu; Yan-jun Zhang; Jian-dong Wang; Yi-qiong Zheng; Jie Li; Bing Ma; Xin Song
Journal:  Med Oncol       Date:  2010-09-25       Impact factor: 3.064

2.  Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Jason R Brown; Michael P DiGiovanna; Brigid Killelea; Donald R Lannin; David L Rimm
Journal:  Lab Invest       Date:  2013-11-04       Impact factor: 5.662

3.  Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.

Authors:  András Vörös; Erika Csörgő; Bence Kővári; Péter Lázár; Gyöngyi Kelemen; Orsolya Rusz; Tibor Nyári; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2014-05-25       Impact factor: 3.201

4.  Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Authors:  Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su
Journal:  Clin Breast Cancer       Date:  2012-04       Impact factor: 3.225

5.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

Review 6.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Authors:  Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

7.  COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients.

Authors:  Bar Chikman; Sergey Vasyanovich; Ron Lavy; Liliana Habler; Gleb Tolstov; Andronik Kapiev; Ariel Halevy; Judith Sandbank
Journal:  Med Oncol       Date:  2014-05-10       Impact factor: 3.064

8.  Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.

Authors:  Ksenija Kanjer; Svetislav Tatić; Zora Nešković-Konstantinović; Zaki Abu Rabi; Dragica Nikolić-Vukosavljević
Journal:  Pathol Oncol Res       Date:  2013-03-24       Impact factor: 3.201

9.  Lateral differences in Ki-67 in breast cancer.

Authors:  Alexey Petrovich Dmitrenko
Journal:  Mol Clin Oncol       Date:  2016-04-04

10.  Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?

Authors:  Zijing Zhang; Wei Zhang; Yiting Jin; Hongying Wang; Fei Gu; Jian Zhou; Zhengyin Lao; Zude Xu; Feng Tang; Liping Zou; Weijun Tang; Rong Lu; Qiang Zou
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.